Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.
Leuk Res. 2002 Sep;26(9):817-20. doi: 10.1016/s0145-2126(02)00020-6.
Leuk Res. 2002.
PMID: 12127556